A Trial to Evaluate treatment with NLY01 in Early-Stage Parkinson's Disease (H-46769)
A Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of 36 weeks treatment with NLY01 in Early-Stage Parkinson's Disease (Pegylated Exenatide-GLP-1R Agonist) Potentially disease modifying trial.
Treatments that reverse, stop, or slow down the progressive loss of neuron function in patients with Parkinson's disease does not currently exist.
The PRISM Parkinson's Research Study is evaluating an investigational drug to determine if it might slow down the progression of PD. By participating in this study, you could help advance the development of treatment options for this disease.
To participate in this study, patients must be:
- 30 to 80 years old
- have early-stage Parkinson's disease
- not be on any current treatments for PD